1. Mountain A. Gene therapy: the first decade. Trends Biotechnol 2000; 18:119-128.

2. Pfeifer A, Verma IM. Gene therapy: promises and problems. Annu Rev Genomics Hum Genet 2001; 2:177-211.

3. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:669-672.

4. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-1193.

5. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bor-dignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296:2410-2413.

6. NIH R. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002; 13:3-13.

7. Lemoine N. Risks and benefits of gene therapy for immunodeficiency: a reality check. Gene Therapy 2002; 9:1561-1562.

8. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat. Rev. Genet 2001; 1:91-99.

9. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60:249-271.

10. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12:861-870.

11. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7:33-40.

12. Johnson-Saliba M, Jans DA. Gene therapy: optimising DNA delivery to the nucleus. Curr Drug Targets 2001; 2:371-399.

13. Niidome T, Huang L. Gene Therapy Progress and Prospects: Nonviral vectors. Gene Ther 2002; 9:1647-1652.

14. Rubanyi GM. The future of human gene therapy. Mol Aspects Med 2001; 22:113-142.

15. Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE, Gerson SL. Cancer gene therapy: scientific basis. Annu Rev Med 2002; 53:437-452.

16. Kay MA CM, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Taj SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.

17. Fischer A, Hacein-Bey S, Cavazzana-Calvo M. Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol 2002; 2:615-621.

18. Griesenbach U, Ferrari S, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2002; 9:1344-1350.

19. Verma IM, Somia N. Gene therapy-promises, problems and prospects. Nature 1997; 389:239-242.

20. Walther W, Stein U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. J Mol Med 1996; 74:379-392.

21. Weber W, Fussenegger M. Artificial mammalian gene regulation networks—novel approaches for gene therapy and bioengineering. J Biotechnol 2002; 98:161-187.

22. Hillen W, Berens C. Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu Rev Microbiol 1994; 48:345-369.

23. Gatz C, Quail PH. Tn10-encoded tet repressor can regulate an operator-containing plant promoter. Proc Natl Acad Sci U S A 1988; 85:1394-1397.

24. Gossen M, Bonin AL, Bujard H. Control of gene activity in higher eukaryotic cells by prokaryotic regulatory elements. Trends Biochem Sci 1993; 18:471-475.

25. Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, Eriksson E. Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther 1998; 9:1939-1950.

26. Gossen M, Bujard H. 12. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992; 89:5547-5551.

27. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268:1766-1769.

28. Baron U, Bujard H. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol 2000; 327:401-421.

29. Gossen M, Bujard H. Tetracyclines in the control of gene expression in eukaryotes. Tetracyclines in Biology, Chemistry and Medicine. Nelson M, Hillen W, Greenwald RA, Eds. Switzerland: Birkhauser Verlga, 2001.

30. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline-de-pendent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 2000; 97:7963-7968.

31. Lamartina S, Roscilli G, Rinaudo CD, Sporeno E, Silvi L, Hillen W, Bujard H, Cortese R, Ciliberto G, Toniatti C. Stringent control of gene expression in vivo by using novel doxycy-cline-dependent trans-activators. Hum Gene Ther 2002; 13: 199-210.

Knott A, Garke K, Urlinger S, Guthmann J, Muller Y, Thell-mann M, Hillen W. Tetracycline-dependent gene regulation: combinations of transregulators yield a variety of expression windows. Biotechniques 2002; 32:796, 798, 800 passim.. Lamartina S, Silvi L, Roscilli G, Casimiro D, Simon AJ, Dav-ies M-E, Shiver JW, Rinaudo CD, Zampaglione I, Fattori E, Colloca S, Paz OG, Laufer R, Bujard H, Cortese R, Ciliberto G, Toniatti C. Construction of an rtTA2s-M2/tTSkid-based transcription regulatory switch which displays no basal activity, great inducibility and high responsiveness to Doxycycline in mice and non-human primates. Mol Ther 2003; in press. Baron U, Gossen M, Bujard H. Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res 1997; 25: 2723-2729.

Witzgall R, O'Leary E, Leaf A, Onaldi D, Bonventre JV. The Kruppel-associated box-A (KRAB-A) domain of zinc finger proteins mediates transcriptional repression. Proc Natl Acad Sci U S A 1994; 91:4514-4518.

Deuschle U, Meyer WK, Thiesen HJ. Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 1995; 15: 1907-1914.

Rossi FM, Guicherit OM, Spicher A, Kringstein AM, Fatyol K, Blakely BT, Blau HM. Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. Nat Genet 1998; 20:389-393. Freundlieb S, Schirra-Muller C, Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1999; 1: 4-12.

McGee Sanftner LH, Rendahl KG, Quiroz D, Coyne M, Ladner M, Manning WC, Flannery JG. P 1. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol Ther 2001; 3:688-696. Rendahl KG, Quiroz D, Ladner M, Coyne M, Seltzer J, Manning WC, Escobedo JA. Tightly regulated long-term erythro-poietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors. Hum Gene Ther 2002; 13: 335-342.

Zhu Z, Ma B, Homer RJ, Zheng T, Elias JA. Use of the tetracy-cline-controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice. J Biol Chem 2001; 276:25222-25229.

Perez N, Plence P, Millet V, Greute D, Minot C, Noel D, Danos O, Jorgensen C, Apparailly F. Tetracycline transcrip-tional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis. Hum Gene Ther 2002; 13:2161-2172.

Wilsey J, Zolotukhin S, Prima V, Shek EW, Matheny MK, Scarpace PJ. Hypothalamic delivery of doxycycline-inducible leptin gene allows for reversible transgene expression and physiological responses. Gene Ther 2002; 9:1492-1499. Rossi FM, Kringstein AM, Spicher A, Guicherit OM, Blau HM. Transcriptional control: rheostat converted to on/off switch. Mol Cell 2000; 6:723-728.

Hoffmann A, Villalba M, Journot L, Spengler D. A novel tetracycline-dependent expression vector with low basal expression and potent regulatory properties in various mammalian cell lines. Nucleic Acids Res 1997; 25:1078-1079. Leuchtenberger S, Perz A, Gatz C, Bartsch JW. Conditional cell ablation by stringent tetracycline-dependent regulation of barnase in mammalian cells. Nucleic Acids Res 2001; 29:E76.

47. Rang A, Will H. The tetracycline-responsive promoter contains functional interferon-inducible response elements. Nucleic Acids Res 2000; 28:1120-1125.

48. Rendahl KG, Leff SE, Otten GR, Spratt SK, Bohl D, Van Roey M, Donahue BA, Cohen LK, Mandel RJ, Danos O, Snyder RO. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat Biotechnol 1998; 16: 757-761.

49. Haberman RP, McCown TJ, Samulski RJ. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 1998; 5:1604-1611.

50. Corti O, Sabate O, Horellou P, Colin P, Dumas S, Buchet D, Buc-Caron MH, Mallet J. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural. Nat Biotechnol 1999; 7: 349-354.

51. Kafri T, van Praag H, Gage FH, Verma IM. Lentiviral vectors: regulated gene expression. Mol Ther 2000; 1:516-521.

52. Fitzsimons HL, Mkenzie JM, During MJ. Insulators coupled to a minimal bidirectional tet cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain. Gene Ther 2001; 8:1675-1681.

53. Regulier E, Pereira de Almeida L, Sommer B, Aebisher P, Deglon N. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiv-iral vectors in the quinolinic acid rat model of Huntington's disease. Hum. Gene Ther 2002; 13:1981-1990.

54. Gu J, Zhang L, Huang X, Lin T, Yin M, Xu K, Ji L, Roth JA, Fang B. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 2002; 21:4757-4764.

55. Bohl D, Salvetti A, Moullier P, Heard JM. Control of erythro-poietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 1998; 92: 1512-1517.

56. Harding TC, Geddes BJ, Murphy D, Knight D, Uney JB. 6. Switching transgene expression in the brain using an adenovi-ral tetracycline-regulatable system. Nat Biotechnol 1998; 16: 553-555.

57. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, Costa P, Mathiesen I, Cortese R, Ciliberto G, Laufer R, La Monica N, Fattori E. Efficient and regulated erythropoietin production by naked DNA injection and muscle electropora-tion. Proc Natl Acad Sci U S A 1999; 96:6417-6422.

58. Favre D, Blouin V, Provost N, Spisek R, Porrot F, Bohl D, Marme F, Cherel Y, Salvetti A, Hurtrel B, Heard JM, Riviere Y, Moullier P. Lack of an immune response against the tetracy-cline-dependent transactivator correlates with long-term doxy-cycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 2002; 76:11605-11611.

59. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96:823-833.

60. Mizuguchi H, Hayakawa T. The tet-off system is more effective than the tet-on system for regulating transgene expression in a single adenovirus vector. J Gene Med 2002; 4:240-247.

61. Dejneka NS, Auricchio A, Maguire AM, Ye X, Gao GP, Wilson JM, Bennett J. Pharmacologically regulated gene expression in the retina following transduction with viral vectors. Gene Ther 2001; 8:442-446..

62. Aurisicchio L, Bujard H, Hillen W, Cortese R, Ciliberto G, La Monica N, Palombo F. Regulated and prolonged expression of mIFN(alpha) in immunocompetent mice mediated by a helper-dependent adenovirus vector. Gene Ther 2001; 8: 1817-1825.

63. Salucci V, Scarito A, Aurisicchio L, Lamartina S, Nicolaus G, Giampaoli S, Gonzalez-Paz O, Toniatti C, Bujard H, Hillen W, Ciliberto G, Palombo F. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Ther 2002; 9:1415-1421.

64. Klein NC, Cunha BA. Tetracyclines. Med. Clin. North Am 1995; 79:789-801.

65. Helbl V, Hillen W. Stepwise selection of TetR variants recognizing tet operator 4C with high affinity and specificity. J Mol Biol 1998; 276:313-318.

66. Baron U, Schnappinger D, Helbl V, Gossen M, Hillen W, Bujard H. Generation of conditional mutants in higher eukary-otes by switching between the expression of two genes. Proc Natl Acad Sci U S A 1999; 96:1013-1018.

67. Urlinger S, Helbl V, Guthmann J, Pook E, Grimm S, Hillen W. The p65 domain from NF-kappaB is an efficient human activator in the tetracycline-regulatable gene expression system. Gene 2000; 247:103-110.

68. Akagi K, Kanai M, Saya H, Kozu T, Berns A. A novel tetracy-cline-dependent transactivator with E2F4 transcriptional activation domain. Nucleic Acids Res 2001; 29:E23.

69. Latta-Mahieu M, Rolland M, Caillet C, Wang M, Kennel P, Mahfouz I, Loquet I, Dedieu JF, Mahfoudi A, Trannoy E, Thuillier V. Gene transfer of a chimeric trans-activator is im-munogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13:1611-1620.

70. Miller M, Bassler BL. Quorom sensing in bacteria. Annu Rev Microbiol 2001; 55:165-199.

71. Fuqua W, Winans SC. A LuxR-Luxl type regulatory system activates Agrobacterium Ti plasmid conjugal transfer in the presence of a plant tumor metabolite. J Bacteriol 1994; 176: 2796-2806.

72. Hwang D, Li PL, Zhang L, Piper KR, Cook DM, Tate ME, Farrand SK. Tral, a Luxl homologue, is responsible for production of conjugation factor, the Ti Plasmid N-acylhomoserine lactone autoinducer. PNAS 1994; 91:4639-4643.

73. Zhang L, Murphy PJ, Kerr A, Tate ME. Agrobacterium conjugation and gene regulation by N-acyl-L-homoserine lactones. Nature 1993; 362:446-448.

74. Piper KR, Beck von Bodman S, Farrand SK. Conjugation factor of Agrobacterium tumefaciens regulates Ti plasmid transfer by autoinduction. Nature 1993; 362:448-450.

75. Fuqua C, Winans SC. Conserved cis-acting promoter elements are required for density-dependent transcription of Agrobact-erium tumefaciens conjugal transfer genes. J Bacteriol 1996; 178:435-440.

76. Zhang RG, Pappas T, Brace JL, Miller PC, Oulmassov T, Molyneaux JM, Anderson JC, Bashkin JK, Winans SC, Joa-chimiak A. Structure of a bacterial quorum-sensing transcription factor complexed with pheromone and DNA. Nature 2002; 417:971-974.

77. Vannini A, Volpari C, Gargioli C, Muraglia E, Cortese R, De Francesco R, Neddermann P, Marco SD. The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA. Embo J 2002; 21:4393-4401.

78. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci U S A 1999; 96:355-360.

79. Neddermann P, Gargioli C, Muraglia E, Sambucini S, Bonelli F, De Francesco R, Cortese R. Embo Rep 2003; 4:159-165, same authorship.

80. Qin Y, Luo ZQ, Smyth AJ, Gao P, Beck von Bodman S, Farrand SK. Quorum-sensing signal binding results in dimer-ization of TraR and its release from membranes into the cytoplasm. Embo J 2000; 19:5212-5221.

81. Zhu J, Winans SC. The quorum-sensing transcriptional regulator TraR requires its cognate signaling ligand for protein folding, protease resistance, and dimerization. Proc Natl Acad Sci USA 2001; 98:1507-1512.

82. Yates E, Philipp B, Buckley C, Atkinson S, Chhabra SR, Sock-ett RE, Goldner M, Dessaux Y, Camara M, Smith H, Williams P. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia Pseudotuberculosis and Pseudomonas aer-uginosa. Infect Immun 2002; 70:5635-5646.

83. Fussenegger M, Morris RP, Fux C, Rimann M, von Stockar B, Thompson CJ, Bailey JE. Streptogramin-based gene regulation systems for mammalian cells. Nat Biotechnol 2000; 18: 1203-1208.

84. Barriere J, Bouanchaud DH, Desnottes JF, Pereis JM. Strepto-gramin analogues. Expert Opin Invest. Drugs 1994; 3: 115-131.

85. Roberts M. Resistance to tetracycline, macrolide-lincosamide-streptogramin, trimethoprim and sulfonamide drug classes. Mol. Biotechnol 2002; 20:261-284.

86. Weber W, Fux C, Daoud-el Baba M, Keller B, Weber CC, Kramer BP, Heinzen C, Aubel D, Bailey JE, Fussenegger M. Macrolide-based transgene control in mammalian cells and mice. Nat Biotechnol 2002; 20:901-907.

87. Weber W, Kramer BP, Fux C, Keller B, Fussenegger M. Novel promoter/transactivator configurations for macrolide- and streptogramin-responsive transgene expression in mammalian cells. J Gene Med 2002; 4:676-686.

88. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. Controlling signal transduction with synthetic ligands. Science 1993; 262:1019-1024.

89. Crabtree GR, Schreiber SL. Three-part inventions: intracellu-lar signaling and induced proximity. Trends Biochem Sci 1996; 21:418-422.

90. Clackson T. Regulated gene expression systems. Gene Ther 2000; 7:120-125.

91. Wells WA. Getting gene therapy under control. ARIAD Pharmaceuticals. Inc. Chem Biol 2001; 8:117-119.

92. Pollock R, Clackson T. Dimerizer-regulated gene expression. Curr Opin Biotechnol 2002; 13:459-467.

93. Amara JF, Courage NL, Gilman M. Cell surface tagging and a suicide mechanism in a single chimeric human protein. Hum Gene Ther 1999; 10:2651-2655.

94. Ptashne M. How eukaryotic transcriptional activators work. Nature 1988; 335:683-689.

95. Fields S, Song O. A novel genetic system to detect proteinprotein interactions. Nature 1989; 340:245-246.

96. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Bura-koff SJ, Crabtree G, Schreiber SL. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A 1990; 87:9231-9235.

97. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-ar-resting rapamycin-receptor complex. Nature 1994; 369: 756-758.

98. Abraham R. Mammalian target of rapamycin: immosuppres-sive drugs uncover a novel pathway of cytokine receptor signalling. Curr Opin Immun 1998; 10:330-336.

99. Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A 1995; 92:4947-4951.

Pomerantz JL, Sharp PA, Pabo CO. Structure-based design of transcription factors. Science 1995; 267:93-96. Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T, Magari SR, Phillips T, Courage NL, Cerasoli F, Holt DA, Gilman M. A humanized system for pharmacologic control of gene expression. Nat Med 1996; 2:1028-1032. Blair WS, Bogerd HP, Madore SJ, Cullen BR. Mutational analysis of the transcription activation domain of RelA: identification of a highly synergistic minimal acidic activation module. Mol Cell Biol 1994; 14:7226-7234.

Pollock R, Issner R, Zoller K, Natesan S, Rivera VM, Clackson T. Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci U S A 2000; 97:13221-13226.

Natesan S, Molinari E, Rivera VM, Rickles RJ, Gilman M. A general strategy to enhance the potency of chimeric transcrip-tional activators. Proc Natl Acad Sci U S A 1999; 96: 13898-13903.

Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP- FK506 complexes. Cell 1991; 66: 807-815.

Clemons P, Gladstone BG, Seth A, Chao ED, Foley MA, Schreiber SL. Synthesis of calcineurin-resistant derivatives of FK506 and selection of compensatory receptors. Chemistry and Biology 2002; 9:49-61.

Rivera VM, Ye X, Courage NL, Sachar J, Cerasoli F, Wilson JM, Gilman M. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci U S A 1999; 96:8657-8662.

Magari SR, Rivera VM, Iuliucci JD, Gilman M, Cerasoli FJr. Pharmacologic control of a humanized gene therapy system implanted into nude mice. J Clin Invest 1997; 100:2865-2872. Go WY, Ho SN. Optimization and direct comparison of the dimerizer and reverse tet transcriptional control systems. J Gene Med 2002; 4:258-270.

Ye X, Rivera VM, Zoltick P, Cerasoli F, Schnell MA, Gao G, Hughes JV, Gilman M, Wilson JM. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283:88-91.

Auricchio A, Gao GP, Yu QC, Raper S, Rivera VM, Clackson T, Wilson JM. Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Ther 2002; 9:963-971.

Auricchio A, Rivera VM, Clackson T, O'Connor EE, Maguire AM, Tolentino MJ, Bennett J, Wilson JM. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 2002; 6:238-242. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18:723-727. Chong H, Ruchatz A, Clackson T, Rivera VM, Vile RG. A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther 2002; 5:195-203. Abraham R, Wiederrecht GJ. Immunopharmacology of rapa-mycin. Annu Rev Immun 1996; 14:483-510. Snyder SH, Sabatini DM. Immunophilins and the nervous system. Nat Med 1995; 1:32-37.

Shou W, Aghdasi B, Armstrong DL, Guo Q, Bao S, Charng MJ, Mathews LM, Schneider MD, Hamilton SL, Matzuk MM. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 1998; 391:489-492. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 1995; 377:441-446.

119. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273:239-242.

120. Liberies SD, Diver ST, Austin DJ, Schreiber SL. Inducible gene expression and protein translocation using nontoxic lig-ands identified by a mammalian three-hybrid screen. Proc Natl Acad Sci U S A 1997; 94:7825-7830.

121. Luengo JI, Yamashita DS, Dunnington D, Beck AK, Rozamus LW, Yen HK, Bossard MJ, Levy MA, Hand A, Newman-Tarr T. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface. Chem Biol 1995; 2:471-481.

122. Beerli RR, Barbas CF. Engineering polydactyl zinc-finger transcription factors. Nat Biotechnol 2002; 20:135-141.

123. Pollock R, Giel M, Linher K, Clackson T. Regulation of endogenous gene expression with a small-molecule dimerizer. Nat Biotechnol 2002; 20:729-733.

124. Tangri S, LiCalsi C, Sidney J, Sette A. Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem 2002; 9:2191-2199.

125. Althoff E, Cornish VW. A bacterial small-molecule three-hybrid system. Angew Chem Int Ed Eng 2002; 41:2327-2330.

126. Lin H, Abida WM, Sauer RT, Cornish VW. Dexamethasone-methotrexate: an efficient chemical inducer of dimerization in vivo. Am Chem Soc 2000; 122:4247-4248.

127. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Bio-chem 1994; 63:451-486.

128. Picard D. Regulation of protein function through expression of chimaeric proteins. Curr Opin Biotechnol 1994; 5:511-515.

129. Picard D. Posttranslational regulation of proteins by fusions to steroid-binding domains. Methods Enzymol 2000; 327: 385-401.

130. Braselmann S, Graninger P, Busslinger M. A selective tran-scriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc Natl Acad Sci U S A 1993; 90:1657-1661.

131. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992; 69:703-713.

132. Wang Y, O'Malley BW, Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci U S A 1994; 91:8180-8184.

133. Wang Y, Xu J, Pierson T, O'Malley BW, Tsai SY. Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator. Gene Ther 1997; 4:432-441.

134. Abruzzese RV, Godin D, Burcin M, Mehta V, French M, Li Y, O'Malley BW, Nordstrom JL. Ligand-dependent regulation of plasmid-based transgene expression in vivo. Hum Gene Ther 1999; 10:1499-1507.

135. Nordstrom JL. Antiprogestin-controllable transgene regulation in vivo. Curr Opin Biotechnol 2002; 13:453-458.

136. Oligino T, Poliani PL, Wang Y, Tsai SY, O'Malley BW, Fink DJ, Glorioso JC. Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther 1998; 5: 491-496.

137. Ye X, Schillinger K, Burcin MM, Tsai SY, O'Malley BW. Ligand-inducible transgene regulation for gene therapy. Methods Enzymol 2002; 346:551-561.

138. Terada Y, Tanaka H, Tomokazu O, Shimamura H, Inoshita S, Kuwahara M, Akiba T, Sasaki S. Ligand-regulatable eryth-

ropoietin production by plasmid injection and in vivo elec-troporation. Kidney Int 2002; 64:1966-1976.

139. Draghia-Akli R, Malone PB, Hill LA, Ellis KM, Schwartz RJ, Nordstrom JL. Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. Faseb J 2002; 16: 426-428.

140. Abruzzese RV, Godin D, Mehta V, Perrard JL, French M, Nelson W, Howell G, Coleman M, O'Malley BW, Nordstrom JL. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol Ther 2000; 2: 276-287.

141. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997; 48:129-156.

142. Deraedt R, Bonnat C, Busigny M, Chatelet P, Cousty C, Mouren M, Philibert D, Pottier J, Salmon J. Pharmacokinetics of RU486. The antiprogestin steroid RU486 and human fertility control. 1985; 103-122.

143. Kekkonen R, Heikinheimo O, Mandelin E, Lahteenmaki P. Pharmacokinetics of mifepristone after low oral doses. Contraception 1996; 54:229-234.

144. Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol 2002; 101:113-120.

145. Marions L, Danielsson KG, Swahn ML, Bygdeman M. Contraceptive efficacy of low doses of mifepristone. Fertil Steril 1998; 70:813-816.

146. He K, Woolf TF, Hollenberg PF. Mechanism-based inactiva-tion of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 1999; 288:791-797.

147. Beerli RR, Schopfer U, Dreier B, Barbas CF. Chemically regulated zinc finger transcription factors. J Biol Chem 2000; 275: 32617-32627.

148. Xu L, Zerby D, Huang Y, Ji H, Nyanguile OF, de los Angeles JE, Kadan MJ. A versatile framework for the design of ligand-dependent, transgene-specific transcription factors. Mol Ther 2001; 3:262-273.

149. Roscilli G, Rinaudo CD, Cimino M, Sporeno E, Lamartina S, Ciliberto G, Toniatti C. Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor. Mol Ther 2002; 6:653-663.

150. Frain M, Swart G, Monaci P, Nicosia A, Stampfli S, Frank R, Cortese R. The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 1989; 59:145-157.

151. De Simone V, De Magistris L, Lazzaro D, Gerstner J, Monaci P, Nicosia A, Cortese R. LFB3, a heterodimer-forming homeo-protein of the LFB1 family, is expressed in specialized epithe-lia. Embo J 1991; 10:1435-1443.

152. Cereghini S. Liver-enriched transcription factors and hepato-cyte differentiation. Faseb J 1996; 10:267-282.

153. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 1993; 7:232-240.

154. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995; 23:1686-1690.

155. Jordan VC, Murphy CS. Endocrine pharmacology of antiestro-gens as antitumor agents. Endocr Rev 1990; 11:578-610.

156. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. Metabolites, pharmacodynamics, and pharmacokinetics of ta-moxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 1991; 19:36-43.

157. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-1618.

158. Hayes T. Pharmacotherapy for male breast cancer. Expert Opin Pharmacother 2002; 3:701-708.

159. Eltabbakh GH, Mount SL. Tamoxifen and the female reproductive tract. Expert Opin Pharmacother 2001; 2:1399-1413.

160. MacColl GS, Goldspink G, Bouloux PM. Using skeletal muscle as an artificial endocrine tissue. J Endocrinol 1999; 162: 1-9.

161. Orphanides G, Reinberg D. A unified theory of gene expression. Cell 2002; 108:439-451.

162. Riddidorf L. Hormones and drosophilia development. The development of Drosophilia Melanogaster. 1993; 899-939.

163. Koelle M, Talbot WS, Segraves WA, Bender MT, Cherbas P, Hogness DS. The drosophilia EcR gene encodes an ecdysone receptor, a new member of the steroid receptor superfamily. Cell 1991; 67:59-77.

164. Yao TP, Segraves WA, Oro AE, McKeown M, Evans RM. Drosophila ultraspiracle modulates ecdysone receptor function via heterodimer formation. Cell 1992; 71:63-72.

165. Thormeyer D, Tenbaum SP, Renkawitz R, Baniahmad A. EcR interacts with corepressors and harbours an autonomous silencing domain functional in both Drosophila and vertebrate cells. J Steroid Biochem Mol Biol 1999; 68:163-169.

166. Tsai CC, Kao HY, Yao TP, McKeown M, Evans RM. SMRTER, a Drosophila nuclear receptor coregulator, reveals that EcR-mediated repression is critical for development. Mol Cell 1999; 4:175-186.

167. Billas IM, Moulinier L, Rochel N, Moras D. Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects. J Biol Chem 2001; 276:7465-7474.

168. Clayton GM, Peak-Chew SY, Evans RM, Schwabe JW. The structure of the ultraspiracle ligand-binding domain reveals a nuclear receptor locked in an inactive conformation. Proc Natl Acad Sci U S A 2001; 98:1549-1554.

169. Rastinejad F. Retinoid X receptor and its partners in the nuclear receptor family. Curr Opin Struct Biol 2001; 11:33-38.

170. Thomas HE, Stunnenberg HG, Stewart AF. Heterodimeriza-tion of the Drosophila ecdysone receptor with retinoid X receptor and ultraspiracle. Nature 1993; 362:471-475.

171. Yao TP, Forman BM, Jiang Z, Cherbas L, Chen JD, McKeown M, Cherbas P, Evans RM. Functional ecdysone receptor is the product of EcR and Ultraspiracle genes. Nature 1993; 366: 476-479.

172. Christopherson KS, Mark MR, Bajaj V, Godowski PJ. Ecdy-steroid-dependent regulation of genes in mammalian cells by a Drosophila ecdysone receptor and chimeric transactivators. Proc Natl Acad Sci U S A 1992; 89:6314-6318.

173. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A 1996; 93:3346-3351.

174. Karns LR, Kisielewski A, Gulding KM, Seraj JM, Theo-dorescu D. Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts. BMC Biotechnol 2001; 1:11.

175. Suhr ST, Gil EB, Senut MC, Gage FH. High level transactiva-tion by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc Natl Acad Sci U S A 1998; 95:7999-8004.

176. Hoppe UC, Marban E, Johns DC. Adenovirus-mediated indu-cible gene expression in vivo by a hybrid ecdysone receptor. Mol Ther 2000; 1:159-164.

177. Subbarayan V, Mark M, Messadeq N, Rustin P, Chambon P, 180. Kastner P. RXRalpha overexpression in cardiomyocytes causes dilated cardiomyopathy but fails to rescue myocardial hypoplasia in RXRalpha-null fetuses. J Clin Invest 2000; 105: 181. 387-394.

178. Hoppe UC, Marban E, Johns DC. Molecular dissection of cardiac repolarization by in vivo Kv4.3 gene transfer. J Clin Invest

2000; 105:1077-1084. 182.

179. Dhadialla TS, Carlson GR, Le DP. New insecticides with ec-dysteroidal and juvenile hormone activity. Annu Rev Entomol 1998; 43:545-569.

Dinan L, Savchenko T, Whiting P. On the distribution of phy-toecdysteroids in plants. Cell Mol Life Sci 2001; 58: 1121-1132.

Saez E, Nelson MC, Eshelman B, Banayo E, Koder A, Cho GJ, Evans RM. Identification of ligands and coligands for the ecdysone-regulated gene switch. Proc Natl Acad Sci USA 2000; 97:14512-14517.

Kumar MB, Fujimoto T, Potter DW, Deng Q, Palli SR. A single point mutation in ecdysone receptor leads to increased ligand specificity: implications for gene switch applications. Proc Natl Acad Sci U S A 2002; 99:14710-14715.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment